ArticleAntimicrobial agents and chemotherapy2019
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 69 citations in OpenAlex.
- The addition of amoxicillin improves the efficacy of the imipenem-avibactam combination againstAntimicrobial agents and chemotherapy · 2025Article
- Novel C5α-substituted carbapenems enhanceAntimicrobial agents and chemotherapy · 2025Article
- Durlobactam in combination with β-lactams to combatAntimicrobial agents and chemotherapy · 2025Article
- Evolution toward extremely high imipenem resistance inAntimicrobial agents and chemotherapy · 2024Article
- Evolution toward extremely high imipenem resistance inAntimicrobial agents and chemotherapy · 2024Article
- Evolution towards extremely high β-lactam resistance inbioRxiv : the preprint server for biology · 2024Article
- Exploring antibiotic resistance mechanisms inFrontiers in microbiology · 2024Review
- Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.Current topics in medicinal chemistry · 2024Review
- Repurposing miconazole and tamoxifen for the treatment of Mycobacterium abscessus complex infections through in silico chemogenomics approach.World journal of microbiology & biotechnology · 2023Article
- Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice.Tuberculosis (Edinburgh, Scotland) · 2022Article
- T405, a New Penem, ExhibitsAntimicrobial agents and chemotherapy · 2022Article
- ERS International Congress 2021: highlights from the Respiratory Infections Assembly.ERJ open research · 2022Review
- Article
- Article
- In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid.Infection and drug resistance · 2022Article
- Article
- "One-Two Punch": Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline.PLoS pathogens · 2021Article
- Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.Antimicrobial agents and chemotherapy · 2021Article
- First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in Mycobacterium abscessus.Antimicrobial agents and chemotherapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.